From MarketBeat:

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Director Janet Dorling recently sold 6,000 shares of the company’s stock at an average price of $23.86, totaling $143,160.00. She previously sold 6,000 shares on December 11th at an average price of $20.07, totaling $120,420.00. The stock currently trades at $23.36 with a market cap of $2.65 billion. (Summary 1)

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) last reported an earnings per share (EPS) of -0.32, falling short of analysts’ consensus estimates of -0.30. Analysts predict CymaBay Therapeutics, Inc. will post -0.95 EPS for the current fiscal year. (Summary 2)

Several equities research analysts have given CymaBay Therapeutics a rating. One analyst rated the stock as “sell”, twelve rated it as “buy”, and one rated it as “strong buy”, resulting in a consensus “Moderate Buy” rating. Their average price target is $22.64. (Summary 3)

Institutional investors have made several modifications to their holdings of CBAY. Approximately 95.03% of the stock is owned by institutional investors and hedge funds. (Summary 4)

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on the development of therapies to treat liver and other chronic diseases. Their lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta for the treatment of autoimmune liver disease and primary biliary cholangitis (PBC). (Summary 5)



Read more: Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stock